Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer — the use of complete response rate as the primary endpoint in phase II trials
- 1 May 2001
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 32 (2) , 155-162
- https://doi.org/10.1016/s0169-5002(00)00220-8
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- A multicenter randomized phase III study comparing paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as front-line treatment in patients with small cell lung cancer (SCLC)Lung Cancer, 2000
- A phase II study of cisplatin, etoposide, and paclitaxel (PET) with G-CSF in untreated patients with extensive small cell lung cancer: A Southwest Oncology Group trialLung Cancer, 2000
- Cisplatin, Etoposide, and Paclitaxel in the Treatment of Patients With Extensive Small-Cell Lung CarcinomaJournal of Clinical Oncology, 1999
- Factors Influencing the Distribution of Metastases and Survival in Extensive Disease Small Cell Lung CancerActa Oncologica, 1999
- Predictive Factors of Tumor Response and Prognostic Factors of Survival during Lung Cancer ChemotherapyCancer Detection Prevention, 1998
- Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.Journal of Clinical Oncology, 1997
- Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinomaCancer, 1996
- Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.Journal of Clinical Oncology, 1995
- Small Cell Lung Cancer: Analysis of Factors Influencing the Response to Treatment and SurvivalOncology, 1994
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989